Binding to ACE-2 receptor, RBD domain, SARS-CoV-2 variants, South Africa variant B.1.351, Spike protein S1, Spike protein S2, U.K variant B.1.1.7, covid-19, sars-cov-2
Application Notes: Functional Assay: This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2. Can be paired with other antibody for detection in sandwich ELISA format
Flow cytometry neutralizing assay: C-A11 displayed dose dependent blocking of spike proteins (wild type and UK variant) to ACE2 expressing cells.
Affinity assessment of SARS-CoV-2 C-A11 IgG to wild type and B.1.1.7 (UK) S1+S2 trimers. C-A11 possesses very low (pM) KD affinity to both variants.
Flow cytomery neutralizing assay of C-A11 (plotted graphs): ACE2 transfected cells were incubated with biotinylated spike protein (0.5 ug/mL) in the presence or absence of antibody. Binding of spike protein was detected with DyLight488 conjugated StreptAvidin. C-A11 efficiently blocked the binding of wild type and UK variant (B.1.1.7) to ACE2 expressing HEK293 cells.
Binding of C-A11 to SARS-CoV-2 variants (UK and South Africa): C-A11 shows good cross reactivity to both variants B.1.1.7 (UK) and B.1.351 (S. Africa).
* VAT and and shipping costs not included. Errors and price changes excepted
